{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/contraception-assessment/management/assessment-for-specific-contraceptive-methods/","result":{"pageContext":{"chapter":{"id":"5970d6e3-da30-5c77-b143-090babc6df1b","slug":"assessment-for-specific-contraceptive-methods","fullItemName":"Scenario: Assessment for specific contraceptive methods","depth":2,"htmlHeader":"<!-- begin field 782ddd5d-5f38-4cd5-be8d-89c864b7009f --><h2>Scenario: Assessment for specific contraceptive methods</h2><!-- end field 782ddd5d-5f38-4cd5-be8d-89c864b7009f -->","summary":"Covers additional assessment and considerations required for women considering a specific method. This includes natural family planning; sterilization; progestogen-only contraception; combined hormonal contraception; and intrauterine contraception.","htmlStringContent":"<!-- begin item ffc66ac2-d547-41ec-a2a7-422f10843904 --><!-- begin field 98d9163d-eb9f-4058-ab2c-acbc015a3ec4 --><p>From age 13 years to 60 years (Female).</p><!-- end field 98d9163d-eb9f-4058-ab2c-acbc015a3ec4 --><!-- end item ffc66ac2-d547-41ec-a2a7-422f10843904 -->","topic":{"id":"b3143012-a228-55f5-8507-b5b650690e4c","topicId":"32f1df2c-afc0-4f35-be88-49caf8770b41","topicName":"Contraception - assessment","slug":"contraception-assessment","lastRevised":"Last revised in September 2019","chapters":[{"id":"8d7c8a25-4e93-5a42-928f-f6611bb74f8b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"f6467a38-cb74-5956-9113-c5ea6b3e26b3","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6121a83b-02e9-52ac-a8f9-0998004484bc","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"07b5f362-627f-5d8a-8d01-b917142582c2","slug":"changes","fullItemName":"Changes"},{"id":"0df9a885-e331-5bb2-aa56-e9c271c953dc","slug":"update","fullItemName":"Update"}]},{"id":"699be09a-1785-5ab5-bf3b-cf106ce69b83","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d59c7a2c-4736-5055-b01b-29e6039bc23b","slug":"goals","fullItemName":"Goals"},{"id":"8e96e0e4-38c0-5981-bfd3-d340e227337e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"df0725fd-cf61-5019-a02b-7c6e05ca6d55","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"86b18852-547f-5859-960f-b4512c2736c1","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"61cea463-ab64-5105-8179-666b624b775b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8d52411f-5b91-53ff-87d9-703de7ff4ff1","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d6a02d9d-3223-585d-89bb-915cc73d1565","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"c6218ca2-8f9c-534f-95be-c1a373a78494","slug":"comparative-effectiveness-of-contraceptive-methods","fullItemName":"Comparative effectiveness of contraceptive methods"},{"id":"1e7241c0-cd2e-5c44-a7d0-01f505a5f6df","slug":"available-contraceptive-methods-in-the-uk","fullItemName":"Available contraceptive methods in the UK"}]},{"id":"f66ce071-5b93-583d-8904-2d6f862b75ea","fullItemName":"Management","slug":"management","subChapters":[{"id":"de31dc4a-7073-5d0b-83fb-9e0af6e49a7b","slug":"issues-to-consider-discuss","fullItemName":"Scenario: Issues to consider and discuss"},{"id":"10acf1be-13df-5c89-8f9c-6c905784040b","slug":"comorbidities-special-situations","fullItemName":"Scenario: Comorbidities and special situations"},{"id":"04a5ef68-fad9-5897-8a64-10294e5004a2","slug":"prescribing-to-young-people","fullItemName":"Scenario: Prescribing to young people"},{"id":"012d4729-63d2-51ca-a18c-bbd593b74fa4","slug":"approaching-the-menopause","fullItemName":"Scenario: Approaching the menopause"},{"id":"5970d6e3-da30-5c77-b143-090babc6df1b","slug":"assessment-for-specific-contraceptive-methods","fullItemName":"Scenario: Assessment for specific contraceptive methods"}]},{"id":"1f285502-649a-5805-a56d-1819aafe2ef0","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2c624d48-ad5c-53e5-afd7-03cbcb0af45d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"040eb257-bbbd-5695-8eda-cde5a6b0991e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"582f4ca4-299f-54d7-ac03-285acee6a6d6","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c6171063-570c-5710-a837-052779620da6","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"278eb9ce-8d46-577d-bc1b-19866cb57433","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7e6a7d96-a9eb-5bb8-bb74-9a82eb3efeaa","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"83baf2bb-d418-5417-9e87-94f055e1ea8a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"f66ce071-5b93-583d-8904-2d6f862b75ea","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"2c1a07e0-a50e-5e39-86f9-b6f6585120fa","slug":"natural-family-planning","fullItemName":"Natural Family Planning","depth":3,"htmlHeader":"<!-- begin field 7ee39da1-efb4-4dbd-a4a4-c244121fe753 --><h3>Natural Family Planning</h3><!-- end field 7ee39da1-efb4-4dbd-a4a4-c244121fe753 -->","summary":null,"htmlStringContent":"<!-- begin item f2523691-afe1-4f56-be6a-bb0e3d33f505 --><!-- end item f2523691-afe1-4f56-be6a-bb0e3d33f505 -->","subChapters":[{"id":"658cd41f-c3a6-5123-90a3-de986c005923","slug":"fertility-awareness-based-methods-of-contraception","fullItemName":"Fertility awareness-based methods of contraception","depth":4,"htmlHeader":"<!-- begin field 8eb7d245-b604-49e8-aec5-a6bf00d997ca --><h4>How should I assess a woman who is considering using fertility awareness-based methods of contraception?</h4><!-- end field 8eb7d245-b604-49e8-aec5-a6bf00d997ca -->","summary":null,"htmlStringContent":"<!-- begin item e934103f-6b6a-49cd-afa4-a6bf00d996e3 --><!-- begin field 77a565ac-f6f1-4d9d-93be-a6bf00d997ca --><ul><li>Fertility awareness-based methods of contraception are not recommended, as there is limited evidence of efficacy compared to more effective methods.  For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/contraception-assessment/background-information/comparative-effectiveness-of-contraceptive-methods/\">How effective are the available contraceptive methods?</a>.</li><li>In addition to a general assessment to decide on a suitable method of contraception, the following specific assessment is advised for women considering fertility awareness-based methods.<ul><li><strong>Check the World Health Organization (WHO)</strong> <a href=\"http://apps.who.int/iris/bitstream/10665/181468/1/9789241549158_eng.pdf?ua=1\" data-hyperlink-id=\"87bd93d5-bb13-44ef-ad76-a98f01240583\">Medical eligibility criteria for contraceptive use</a>. <ul><li>Fertility awareness-based methods are not covered in the UK Medical Eligibility Criteria.</li></ul></li><li><strong>Ask about conditions or factors that could affect fertility signs</strong>, making the fertility awareness–based methods difficult to use, for example:<ul><li>Any conditions that affect the ovaries or menstrual bleeding (for example stroke, serious liver disease, hyperthyroid, hypothyroid, or cervical cancer).</li><li>Breastfeeding, postpartum, or recent termination of pregnancy. </li><li>The use of drugs that affect cervical mucus for example lithium, tricyclic antidepressants, and some antibiotics.<ul><li>If the woman wishes to continue with the fertility awareness-based method, advise her to use basal body temperature, calendar charting, or urine hormone levels methods.</li></ul></li><li>Irregular menstrual cycle (especially in younger girls and older women), vaginal bleeding between periods, or heavy or long monthly bleeding. Irregular periods may make predicting fertile times with the calendar charting method very difficult or even impossible.<ul><li>If the woman wishes to continue with the fertility awareness-based method, advise her to use basal body temperature, cervical mucus, or urine hormone level methods.</li></ul></li><li>Any infections in the last 3 months (in particular, sexually transmitted infections [STIs], pelvic inflammatory disease [PID], or vaginal infections), as vaginal discharge makes methods which reply on cervical secretions more difficult to use — once an infection is treated and reinfection is avoided, the fertility awareness–based methods can be used more easily.</li></ul></li></ul></li><li>For more information on fertility awareness-based methods of contraception, see <a class=\"topic-reference external-reference\" href=\"/topics/contraception-natural-family-planning/management/fertility-awareness-methods/\">Scenario: Fertility awareness methods</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-natural-family-planning/\">Contraception - natural family planning</a>.</li></ul><!-- end field 77a565ac-f6f1-4d9d-93be-a6bf00d997ca --><!-- end item e934103f-6b6a-49cd-afa4-a6bf00d996e3 -->","subChapters":[]},{"id":"3142286e-15f8-5d91-b115-16c39aeba385","slug":"lactational-amenorrhoea-methods-of-contraception","fullItemName":"Lactational amenorrhoea methods of contraception","depth":4,"htmlHeader":"<!-- begin field 006a18d5-78e7-4445-abfc-a6bf00d9add9 --><h4>How should I assess a woman who is considering using the lactational amenorrhoea methods of contraception?</h4><!-- end field 006a18d5-78e7-4445-abfc-a6bf00d9add9 -->","summary":null,"htmlStringContent":"<!-- begin item d6c3ad6d-3e67-4810-8836-a6bf00d9ad01 --><!-- begin field 8a2241d3-d9ed-4964-beed-a6bf00d9add9 --><ul><li>In addition to a general assessment to decide on a suitable method of contraception, the following specific assessment is advised for women considering the lactational amenorrhoea method (LAM).<ul><li>If the woman has a condition which makes pregnancy an unacceptable health risk, or it is important to her that she does not get pregnant, advise her that the LAM may not be appropriate for her, as alternative contraceptive methods have lower failure rates.</li><li>Check that the woman meets the criteria for the use of the LAM. Women can use the LAM for the first 6 months after giving birth, provided that all the following conditions are met:<ul><li>Complete amenorrhoea.</li><li>Fully or very nearly fully breastfeeding — a woman is no longer fully, or nearly fully breastfeeding, if the baby is getting less than 85% of its feeds as breast milk.</li><li>Six months or less since the birth of the baby.</li></ul></li><li>For more information, see the section on the <a class=\"topic-reference external-reference\" href=\"/topics/contraception-natural-family-planning/background-information/what-is-it/#the-lactational-amenorrhea-method\">LAM</a> in the CKS topic on on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-natural-family-planning/\">Contraception - natural family planning</a>.</li><li>Ask about other conditions or factors that could make the LAM difficult or not recommended, for example:<ul><li>The use of drugs that are contraindicated in breastfeeding such as mood-altering drugs, reserpine, ergotamine, antimetabolites, ciclosporin, oral corticosteroids (high doses of more than 40 mg per day), bromocriptine, radioactive drugs, lithium, and anticoagulants.</li><li>The baby's health. Breastfeeding can be difficult or contraindicated in infants with certain metabolic disorders or congenital deformities of the mouth, jaw, or palate, and in newborns who are in intensive care.</li><li>The effect of expressing milk on the efficacy of the LAM is not known, but it may be reduced.</li><li>The woman's health and the presence of any condition in which breastfeeding is not advisable, for example HIV (as it can be transmitted through breast milk), or if she has been advised by a healthcare professional not to breastfeed.</li><li>For more information on the LAM, see the <a class=\"topic-reference external-reference\" href=\"/topics/contraception-natural-family-planning/management/lactational-amenorrhea-method/\">Scenario: Lactational amenorrhea method</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-natural-family-planning/\">Contraception - natural family planning</a>.</li></ul></li></ul></li></ul><!-- end field 8a2241d3-d9ed-4964-beed-a6bf00d9add9 --><!-- end item d6c3ad6d-3e67-4810-8836-a6bf00d9ad01 -->","subChapters":[]},{"id":"f7719ec5-894a-5399-a1ca-b7383bdacd15","slug":"basis-for-recommendation-ff7","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 40378e36-96ab-4634-a46f-951b54b90b22 --><h4>Basis for recommendation</h4><!-- end field 40378e36-96ab-4634-a46f-951b54b90b22 -->","summary":null,"htmlStringContent":"<!-- begin item ff795ac8-99e3-490a-a404-9cfa26ab7a1a --><!-- begin field 32c813e2-4683-409c-9f5a-297c17b1eaa2 --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline <em>Fertility awareness method</em><em>s</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2015c</a>] and expert opinion in a medical textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">Hatcher, 2011</a>].</p><!-- end field 32c813e2-4683-409c-9f5a-297c17b1eaa2 --><!-- end item ff795ac8-99e3-490a-a404-9cfa26ab7a1a -->","subChapters":[]}]},{"id":"cb974183-50c2-546a-90ec-84644d23720c","slug":"barrier-methods-spermicides","fullItemName":"Barrier methods and spermicides","depth":3,"htmlHeader":"<!-- begin field a89543da-c512-435b-9965-0db84481ac9e --><h3>How should I assess a woman who is considering using barrier methods and spermicides?</h3><!-- end field a89543da-c512-435b-9965-0db84481ac9e -->","summary":null,"htmlStringContent":"<!-- begin item 9dc890a3-9b1f-4d9c-be22-2e4e244cddcc --><!-- begin field 3289aa3c-5d61-419f-a1c5-44dcb28cb7b6 --><p>In addition to a general assessment to decide on a suitable method of contraception, the following specific assessment is advised for women considering using a cervical cap or diaphragm. </p><ul><li><strong>Conduct a vaginal examination</strong> at the initial fitting of a cap or diaphragm to ensure it is suitable and that it fits correctly.<ul><li>Advise women who are using teratogenic drugs (such as lithium and phenytoin) to consider alternative, more effective methods of contraception (such as progestogen-only injectables or a levonorgestrel intrauterine system [LNG-IUS]).</li><li>The diaphragm and cervical cap are not suitable before 6 weeks postpartum, or 6 weeks following second trimester termination of pregnancy.<ul><li>Advise women to wait 6 weeks after delivery (or second trimester termination) before using the diaphragm or cervical cap, to allow the uterus to return to its pre-pregnancy size and conditions.<ul><li>A different size of cap or diaphragm may be needed postpartum.</li></ul></li></ul></li><li>The diaphragm and cap are not appropriate for women who:<ul><li>Have very poor vaginal muscle tone (this may be a contraindication for the diaphragm).</li><li>Have a shallow pubic ledge (this applies to the diaphragm only).</li><li>Have an abnormality of the vagina.</li><li>Cannot touch their genital area with comfort </li><li>Have a cervix in a position that makes it difficult to fit.</li></ul></li></ul></li><li>In young women and women with special needs, the diaphragm and cervical cap may not be appropriate, given their higher failure rates compared with other methods.</li><li>For more information on barrier methods and spermicides, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-barrier-methods-spermicides/\">Contraception - barrier methods and spermicides</a>.</li></ul><!-- end field 3289aa3c-5d61-419f-a1c5-44dcb28cb7b6 --><!-- end item 9dc890a3-9b1f-4d9c-be22-2e4e244cddcc -->","subChapters":[{"id":"ea993525-5065-5187-81a0-74bbbb96494e","slug":"basis-for-recommendation-c00","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field a2053afc-83c1-42d6-a60b-99d078856d3a --><h4>Basis for recommendation</h4><!-- end field a2053afc-83c1-42d6-a60b-99d078856d3a -->","summary":null,"htmlStringContent":"<!-- begin item c00682be-7a80-4ee2-9311-ef0b9f73ae98 --><!-- begin field 16050d89-c405-4723-b6c7-4fcc3d0f4408 --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline <em>Barrier methods for contraception and STI prevention </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2015b</a>].</p><!-- end field 16050d89-c405-4723-b6c7-4fcc3d0f4408 --><!-- end item c00682be-7a80-4ee2-9311-ef0b9f73ae98 -->","subChapters":[]}]},{"id":"e6342148-0c33-59b7-be18-32edb2a338d2","slug":"sterilization","fullItemName":"Sterilization","depth":3,"htmlHeader":"<!-- begin field 09951df2-109b-4e8a-8884-77e1f791e5d0 --><h3>How should I assess someone who is considering sterilization?</h3><!-- end field 09951df2-109b-4e8a-8884-77e1f791e5d0 -->","summary":null,"htmlStringContent":"<!-- begin item 0c5a57f2-032e-4fa8-aff3-f274e0099ffd --><!-- begin field f94c6e54-b33a-45a9-b688-913b07c2b38b --><p>In addition to a general assessment to decide on a suitable method of contraception, the following specific assessment is advised for people considering sterilization.</p><ul><li><strong>Check the World Health Organization (WHO) Medical Eligibility Criteria for contraceptive use </strong>to ensure that sterilization is a suitable choice for the person<strong>.</strong></li><li><strong>Assess the person's:</strong> <ul><li><strong>M</strong><strong>ental capacity</strong> to make the decision.<ul><li>If there is any doubt about their mental capacity, seek advice from appropriately experienced colleagues (such as a specialist in learning disabilities).</li></ul></li><li><strong>Level of understanding</strong> of the advantages, disadvantages, procedures involved, and relative failure rates of a vasectomy or tubal occlusion.<ul><li>Offer alternative long-term reversible methods of contraception such as hormonal methods (combined hormonal contraceptives, progestogen-only contraceptives) or intrauterine methods.</li></ul></li><li><strong>Risk for later regret</strong>. Take additional care when counselling people who are:<ul><li>Younger than 30 years of age.</li><li>Without children.</li><li>Taking decisions during pregnancy.</li><li>Taking decisions in reaction to the end of a relationship.</li><li>Possibly at risk of coercion by their partner, family, or health or social welfare professionals.</li></ul></li><li><strong>Cultural, religious, psychosocial, psychosexual, and psychological issues.</strong></li></ul></li><li><strong>Also assess</strong> their partner's suitability for sterilization, as the couple's clinical history, present symptoms, or abnormal examination findings may influence which partner goes forward to have sterilization. For example:<ul><li>Vasectomy for the man may be preferable if:<ul><li>The woman has any contraindication to general anaesthesia.</li><li>The woman has had previous abdominal or pelvic surgery — this increases the relative risk of complications and the need for a laparotomy.</li></ul></li><li>Tubal occlusion for the woman may be preferable.<ul><li>If a past history of genital or scrotal surgery in the man increases the risk of complications of vasectomy.</li></ul></li><li>A hysterectomy may be an alternative if significant gynaecological pathology, such as large fibroids or a prolapse, is present.</li></ul></li><li><strong>Perform a scrotal examination</strong> for a man requesting vasectomy to exclude potential problems (for example, a large varicocele or hydrocele may mean that the <em>vas deferens</em> is more difficult to palpate and general anaesthesia is required).</li><li><strong>Perform a bimanual pelvic examination</strong> on a woman requesting tubal occlusion.</li><li>For more information on sterilization, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-sterilization/\">Contraception - sterilization</a>.</li></ul><!-- end field f94c6e54-b33a-45a9-b688-913b07c2b38b --><!-- end item 0c5a57f2-032e-4fa8-aff3-f274e0099ffd -->","subChapters":[{"id":"37cc8870-aeab-5b43-84a5-ee42db9a33ea","slug":"basis-for-recommendation-ffd","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field df756018-dbc4-4428-a1b6-1dbea90779fc --><h4>Basis for recommendation</h4><!-- end field df756018-dbc4-4428-a1b6-1dbea90779fc -->","summary":null,"htmlStringContent":"<!-- begin item ffd92be4-da0a-4ae5-850e-3148f2ebf79c --><!-- begin field 1b31db3a-7f33-46f2-b875-cab9ec48af9a --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline <em>Male and female sterilisation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2014a</a>].</p><!-- end field 1b31db3a-7f33-46f2-b875-cab9ec48af9a --><!-- end item ffd92be4-da0a-4ae5-850e-3148f2ebf79c -->","subChapters":[]}]},{"id":"f1eb9f6c-9a71-5845-9f84-e1f647e6a304","slug":"progestogen-only-contraception","fullItemName":"Progestogen-only contraception","depth":3,"htmlHeader":"<!-- begin field 8941b13a-03bc-4f71-8f86-4dc3d27072f2 --><h3>Progestogen-only contraception</h3><!-- end field 8941b13a-03bc-4f71-8f86-4dc3d27072f2 -->","summary":null,"htmlStringContent":"<!-- begin item c2d2344e-ad0c-4a4c-9d1b-31a066380870 --><!-- end item c2d2344e-ad0c-4a4c-9d1b-31a066380870 -->","subChapters":[{"id":"03128b09-df1d-5b88-9f2b-b96c27aa2a77","slug":"progestogen-only-pill","fullItemName":"Progestogen-only pill","depth":4,"htmlHeader":"<!-- begin field c0ed9964-9eaa-4fad-bf4d-a7a700cba6f3 --><h4>How should I assess a woman considering taking the progestogen-only pill?</h4><!-- end field c0ed9964-9eaa-4fad-bf4d-a7a700cba6f3 -->","summary":null,"htmlStringContent":"<!-- begin item bb967c30-1317-4245-b9d2-a7a700cba4ab --><!-- begin field fbbcc23d-9725-43a0-860e-a7a700cba6f3 --><p>In addition to a general assessment to decide on a suitable method of contraception, the following specific assessment is advised for women considering the progestogen-only pill (POP).</p><ul><li><strong>Check the UK Medical Eligibility Criteria</strong><strong> </strong>to ensure that the woman can safely use a POP.<ul><li>The only UKMEC 4 condition for the POP is current breast cancer.</li><li>The POP should only be used after consultation with an expert (UKMEC 3) in women with a history of breast cancer and no evidence of recurrence for 5 years, women taking liver enzyme-inducing drugs such as rifampicin, and women with a new diagnosis of ischaemic heart disease while using the POP for example.</li></ul></li><li><strong>Check the woman's cervical screening history</strong> to ensure that she has attended routine screening appointments.</li><li>For more information about the POP, see <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-pill/\">Scenario: Progestogen-only pill </a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul><!-- end field fbbcc23d-9725-43a0-860e-a7a700cba6f3 --><!-- end item bb967c30-1317-4245-b9d2-a7a700cba4ab -->","subChapters":[]},{"id":"96552504-22ba-5d06-a7d7-faaf04087ed8","slug":"progestogen-only-implant","fullItemName":"Progestogen-only implant","depth":4,"htmlHeader":"<!-- begin field 05488bad-77c7-42e5-86de-d49e081f19c1 --><h4>How should I assess a woman considering using a progestogen-only implant?</h4><!-- end field 05488bad-77c7-42e5-86de-d49e081f19c1 -->","summary":null,"htmlStringContent":"<!-- begin item 6532ccb1-7c95-467d-a6da-88e541fcc237 --><!-- begin field dee14ce6-7afa-4601-9c3e-e1f79b476647 --><p>In addition to a general assessment to decide on a suitable method of contraception, the following specific assessment is advised for women considering the progestogen-only implant.</p><ul><li><strong>Check the UK Medical Eligibility Criteria</strong> to ensure that the woman can safely use a progestogen-only implant.<ul><li>The only UKMEC 4 condition for the progestogen-only implant is current breast cancer.</li><li>The progestogen-only implant should only be used after consultation with an expert (UKMEC 3), for example in women with a history of breast cancer and no evidence of recurrence for 5 years, women with liver tumours (benign and malignant), and women with unexplained vaginal bleeding (before evaluation).</li></ul></li><li><strong>Check the woman's cervical screening history</strong> to ensure that she has attended routine screening appointments. </li><li>For more information on the progestogen-only implant, see <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-implant/\">Scenario: Progestogen-only implant</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul><!-- end field dee14ce6-7afa-4601-9c3e-e1f79b476647 --><!-- end item 6532ccb1-7c95-467d-a6da-88e541fcc237 -->","subChapters":[]},{"id":"c2bf8d7f-29a5-52ee-a4cf-945b31fc60f3","slug":"progestogen-only-injectable","fullItemName":"Progestogen-only injectable","depth":4,"htmlHeader":"<!-- begin field 24e223d1-17d5-48cf-beee-d84eb20b0abf --><h4>Progestogen-only injectable</h4><!-- end field 24e223d1-17d5-48cf-beee-d84eb20b0abf -->","summary":null,"htmlStringContent":"<!-- begin item 25708704-f425-4f31-94af-33c47175a8d1 --><!-- begin field e548e37d-9080-4fd1-a999-d2c5da1156a9 --><p>In addition to a general assessment to decide on a suitable method of contraception, the following specific assessment is advised for women considering a progestogen-only injectable. </p><ul><li><strong>Check the UK Medical Eligibility Criteria</strong> to ensure that the woman can safely use a progestogen-only injectable.<ul><li>The only UKMEC 4 condition for the progestogen-only injectable is current breast cancer.</li><li>The progestogen-only injectable should only be used after consultation with an expert (UKMEC 3), in women with a history of:<ul><li>Breast cancer and no evidence of recurrence for 5 years. </li><li>Multiple risk factors for arterial cardiovascular disease (for example older age, smoking, diabetes, and hypertension).</li><li>Vascular disease, including angina or other ischaemic heart disease, intermittent claudication, hypertensive retinopathy, stroke, or transient ischaemic attack.</li></ul></li></ul></li><li><strong>Check</strong><strong> the woman's cervical screening history</strong> to ensure that she has attended routine screening appointments.</li><li><strong>Assess the woman's risk of osteoporosis.</strong><ul><li>Consider other methods of contraception for women:<ul><li>Aged under 18 years of age (consider the depot medroxyprogesterone acetate [DMPA] injection only if all other methods of contraception are unsuitable or unacceptable).</li><li>With significant risk factors for osteoporosis. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/\">Osteoporosis - prevention of fragility fractures</a>.</li></ul></li><li>Review the risks and benefits of DMPA injection at least every 2 years, and decide whether treatment can be continued. For more information, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/background-information/risk-factors/\">risk factors</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/osteoporosis-prevention-of-fragility-fractures/\">Osteoporosis - prevention of fragility fractures</a>.</li><li>For more information on the progestogen-only injectable, see <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/management/progestogen-only-injectables/\">Scenario: Progestogen-only injectables</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li></ul><!-- end field e548e37d-9080-4fd1-a999-d2c5da1156a9 --><!-- end item 25708704-f425-4f31-94af-33c47175a8d1 -->","subChapters":[]},{"id":"7ecf55fa-3fb8-5e86-86ad-e40233382c9d","slug":"basis-for-recommendation-93d","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 9c593488-9250-4571-b16c-a7a700ccafbd --><h4>Basis for recommendation</h4><!-- end field 9c593488-9250-4571-b16c-a7a700ccafbd -->","summary":null,"htmlStringContent":"<!-- begin item 93ddf098-9304-4a54-92a2-a7a700ccad9f --><!-- begin field 93939d26-e9ab-46cb-929e-a7a700ccafbd --><h5>Progestogen-only pills</h5><ul><li>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines <em>Progestogen–only pills</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2015d</a>], <em>Quick starting contraception,</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2010a</a>] and the <em>UK Medical Eligibility Criteria for contraceptive use</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2016</a>].</li></ul><h5>Progestogen-only implants</h5><ul><li>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines <em>Progestogen-only implants </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2014b</a>],<em> Quick start contraception </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2010a</a>]<em>, </em>the <em>UK Medical Eligibility Criteria for contraceptive use </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2016</a>] and the National Institute for Health and Care Excellence (NICE) guidance <em>Long-acting reversible contraception</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">NICE, 2014</a>].</li></ul><h5>Progestogen-only injectables</h5><ul><li>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline Progestogen-only injectable [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2014c</a>], the <em>UK Medical Eligibility Criteria for contraceptive use</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2016</a>], and the National Institute for Health and Care Excellence (NICE) guidance <em>Long-acting reversible contraception</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">NICE, 2014</a>].</li></ul><!-- end field 93939d26-e9ab-46cb-929e-a7a700ccafbd --><!-- end item 93ddf098-9304-4a54-92a2-a7a700ccad9f -->","subChapters":[]}]},{"id":"a2efc376-1412-5eaf-b5c8-4f994121fa6b","slug":"combined-hormonal-contraception","fullItemName":"Combined hormonal contraception","depth":3,"htmlHeader":"<!-- begin field 73455764-7daa-4988-b0a8-f57e2bbe07f1 --><h3>How should I assess a woman's suitability for combined hormonal contraception (CHC)?</h3><!-- end field 73455764-7daa-4988-b0a8-f57e2bbe07f1 -->","summary":null,"htmlStringContent":"<!-- begin item 4f37c487-a329-449a-ac5b-891719fb8c7b --><!-- begin field ce6a0f3d-d4e1-49e6-9a32-9c7edefed027 --><p>In addition to a general assessment to decide on a suitable method of contraception, the following specific assessment is advised for women considering combined hormonal contraception (CHC).</p><ul><li><strong>Check the UK Medical Eligibility Criteria</strong><ul><li>CHC is contraindicated due to unacceptable health risks (UKMEC 4) in women with current breast cancer, women who are breastfeeding and are less than 6 weeks postpartum, and women aged 35 years or more and smoking 15 or more cigarettes daily. </li><li>CHC should only be used after consultation with an expert (UKMEC 3) in women with a history of breast cancer and no evidence of recurrence for 5 years, woman taking liver enzyme-inducing drugs such as rifampicin, and women with BMI greater than 35 kg/m<sup>2</sup>.</li><li>For a full list of UKMEC 4 and UKMEC 3 categories, see the <a href=\"https://www.fsrh.org/standards-and-guidance/uk-medical-eligibility-criteria-for-contraceptive-use/\" data-hyperlink-id=\"375a19f1-2014-4b44-aead-a98f0086177d\">UK Medical Eligibility Critera for contraceptive use</a>.</li></ul></li><li><strong>Enquire specifically about:</strong><ul><li>Migraine.</li><li>Cardiovascular risk factors such as smoking, obesity, hypertension, previous venous thromboembolism, hyperlipidaemia, and thrombophilia.</li><li>Past and current medical conditions.</li><li>Family history.</li></ul></li><li>For more information on combined oral contraceptives, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a>.</li></ul><!-- end field ce6a0f3d-d4e1-49e6-9a32-9c7edefed027 --><!-- end item 4f37c487-a329-449a-ac5b-891719fb8c7b -->","subChapters":[{"id":"5d40a318-3073-5ceb-bb6b-1b4884968f59","slug":"basis-for-recommendation-b81","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 53cb255f-e5fb-4ce9-83af-17a3aa0bd152 --><h4>Basis for recommendation</h4><!-- end field 53cb255f-e5fb-4ce9-83af-17a3aa0bd152 -->","summary":null,"htmlStringContent":"<!-- begin item b815dd12-07b6-4573-aaf2-1729eb91e5b5 --><!-- begin field b49ac275-9fc3-4e85-8087-ebd422013d1a --><p>These recommendations are based mainly on the Faculty of Sexual and Reproductive Healthcare clinical guidelines <em>Combined hormonal contraception</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2011d</a>] and the <em>UK Medical Eligibility Criteria for contraceptive use</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2016</a>].</p><!-- end field b49ac275-9fc3-4e85-8087-ebd422013d1a --><!-- end item b815dd12-07b6-4573-aaf2-1729eb91e5b5 -->","subChapters":[]}]},{"id":"ef68500b-3948-566d-85e2-c6f82a6dbecd","slug":"ius-iud","fullItemName":"IUS/IUD","depth":3,"htmlHeader":"<!-- begin field 2a046c78-66e9-4500-9c6b-a8481236aa73 --><h3>How should I assess a woman's suitability to use the levonorgestrel intrauterine system (LNG-IUS) or the copper intrauterine device (Cu-IUD)?</h3><!-- end field 2a046c78-66e9-4500-9c6b-a8481236aa73 -->","summary":null,"htmlStringContent":"<!-- begin item 2de5b9bf-7274-4d80-b8c4-45061640a64b --><!-- begin field 95694374-fce7-4a40-930f-b18dbc4038c6 --><p>In addition to a general assessment to decide on a suitable method of contraception, the following specific assessment is advised for women considering using a levonorgestrel intrauterine device (LNG-IUS) or a copper intrauterine device (Cu-IUD).</p><ul><li><strong>Exclude pregnancy.</strong> If pregnancy is possible, do not insert intrauterine contraception (IUC). Advise the woman to use a barrier method (such as condoms) until pregnancy can be excluded.<ul><li>If the woman does not wish to use a barrier method of contraception, consider one of the following options:<ul><li>Combined hormonal contraception (pill, patch, or vaginal ring).</li><li>Progestogen-only pill.</li><li>Progestogen-only implant.</li><li>Progestogen-only injectable — if other methods are not appropriate or acceptable.</li></ul></li></ul></li><li><strong>Check </strong><strong>the UK Medical Eligibility Criteria </strong>to ensure that IUC is suitable. This will require information from the medical record, clinical history, and clinical examination, which should include bimanual pelvic examination.<ul><li> IUC is a safe option in most women, however it:<ul><li>Is contraindicated (UKMEC 4) in women with current breast cancer (LNG-IUS only), pelvic inflammatory disease, or unexplained vaginal bleeding.</li><li>Should be used with caution, and after consultation with an expert (UKMEC 3), for example in women with uterine fibroids with distortion of the uterine cavity or women with a history of breast cancer and no evidence of recurrence for 5 years (LNG-IUS only).</li></ul></li></ul></li><li><strong>Assess</strong> <strong>the woman's risk of sexually transmitted infections</strong> (STIs) and, when appropriate, advise testing, promote safer sex, and/or refer for sexual health counselling.<ul><li>If the woman is at increased risk of STIs:<ul><li>Test for <em>Chlamydia trachomatis</em> and, in women from areas where gonorrhoea is prevalent, test for <em>Neisseria gonorrhoeae</em>. In asymptomatic women, there is no need to wait for the results or to provide antibiotic prophylaxis before inserting the IUC, provided the woman can be contacted and treated if the test is positive. For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/chlamydia-uncomplicated-genital/\">Chlamydia - uncomplicated genital</a> and <a class=\"topic-reference external-reference\" href=\"/topics/gonorrhoea/\">Gonorrhoea</a>.</li><li>Counsel her (or arrange for counselling) about safe sexual practices.</li><li>Review her decision for choice of contraception, and discuss alternative contraceptive methods or recommend correct and consistent use of condoms with the LNG-IUS.</li></ul></li><li>If the woman requests testing for STIs, perform testing before inserting the device. There is no need to wait for the results or to provide antibiotic prophylaxis before inserting the IUD, provided the woman can be contacted and treated if the test is positive.<ul><li>If the woman has symptoms of a possible STI, and/or pelvic inflammatory disease (PID), delay IUC insertion and offer a bridging method of contraception if necessary.</li></ul></li></ul></li><li><strong>If the woman has unexplained vaginal bleeding </strong>that suggests an underlying medical condition (such as bleeding between her periods or after sexual intercourse):<ul><li>Do not insert the LNG-IUS until the cause of bleeding has been diagnosed.</li><li>Offer an alternative method of contraception.</li></ul></li><li>For more information on the LNG-IUS and the Cu-IUD, see <a class=\"topic-reference external-reference\" href=\"/topics/contraception-ius-iud/management/levonorgestrel-intrauterine-system/\">Scenario: Levonorgestrel intrauterine system</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-ius-iud/management/copper-intrauterine-device/\">Scenario: Copper intrauterine device</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-ius-iud/\">Contraception - IUS/IUD</a>.</li></ul><!-- end field 95694374-fce7-4a40-930f-b18dbc4038c6 --><!-- end item 2de5b9bf-7274-4d80-b8c4-45061640a64b -->","subChapters":[{"id":"99487a0b-3298-529b-bceb-f49e1bceb6af","slug":"basis-for-recommendation-4fa","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field b94f31d8-bb3a-4797-8ab9-85677b2a57f7 --><h4>Basis for recommendation</h4><!-- end field b94f31d8-bb3a-4797-8ab9-85677b2a57f7 -->","summary":null,"htmlStringContent":"<!-- begin item 4fac87be-6934-4479-b5f2-ea21733cb923 --><!-- begin field 651ff3f2-d584-483c-b4f2-37e88ac6da68 --><p>These recommendations are based mainly on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline <em>Intrauterine contraception</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2015a</a>], the <em>UK Medical Eligibility Criteria for contraceptive use</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">FSRH, 2016</a>] and the National Institute for Health and Care Excellence guideline <em>Long–acting reversible contraception </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-assessment/references/\">NICE, 2014</a>].</p><!-- end field 651ff3f2-d584-483c-b4f2-37e88ac6da68 --><!-- end item 4fac87be-6934-4479-b5f2-ea21733cb923 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}